Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function

Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function

Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal immunity induced by environmental factors in genetically suscepti...

Full description

Bibliographic Details
Main Authors:	Mijeong Son, I Seul Park, Soochan Kim, Hyun Woo Ma, Ji Hyung Kim, Tae Il Kim, Won Ho Kim, Jaeyong Han, Seung Won Kim, Jae Hee Cheon
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Immunology
Subjects:	Bacteroides vulgatus inflammatory bowel disease potassium-competitive acid blocker proton pump inhibitor gut barrier function
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.870817/full

Similar Items

Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Eradication
by: Seokin Kang, et al.
Published: (2024-06-01)

Effects of Bombyx batryticatus extract on hyperglycemia and gut microbiota in diabetic mice induced by streptozotocin and high-fat diet
by: Hwa Lee, et al.
Published: (2024-11-01)

Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
by: Jung Won Lee, et al.
Published: (2021-01-01)

Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
by: Yoon Jin Choi, et al.
Published: (2022-07-01)

Assessment of the efficacy of on-demand tegoprazan therapy in gastroesophageal reflux disease through a randomized controlled trial
by: Sun Hyung Kang, et al.
Published: (2025-01-01)

JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases
by: Jin Mo Ku, et al.
Published: (2023-06-01)

Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study
by: Yoon Suk Jung, et al.
Published: (2023-09-01)

Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers
by: Jong Kyu Park
Published: (2023-09-01)

Bacteroides vulgatus attenuates experimental mice colitis through modulating gut microbiota and immune responses
by: Liyun Liu, et al.
Published: (2022-11-01)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
by: Sejung Hwang, et al.
Published: (2021-11-01)

Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
by: Sungpil Han, et al.
Published: (2023-01-01)

Vibrio vulnificus induces the death of a major bacterial species in the mouse gut via cyclo-Phe-Pro
by: Jeong-A Kim, et al.
Published: (2021-07-01)

Bacteroides vulgatus alleviates dextran sodium sulfate-induced colitis and depression-like behaviour by facilitating gut-brain axis balance
by: Xing Wu, et al.
Published: (2023-11-01)

Commensal-derived metabolites govern Vibrio cholerae pathogenesis in host intestine
by: Jin Sun You, et al.
Published: (2019-09-01)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
by: Deok Yong Yoon, et al.
Published: (2021-09-01)

Redefining GERD management: The emerging role of potassium-competitive acid blockers
by: Vania Azalia Gunawan, et al.
Published: (2025-03-01)

Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
by: Jihye Park, et al.
Published: (2021-10-01)

Potassium-competitive acid blocker-associated gastric mucosal lesions
by: Kimitoshi Kubo, et al.
Published: (2024-07-01)

Role of Potassium-competitive Acid Blockers in the Treatment of Gastric Acid-related Disorders
by: Mun Young Cho, et al.
Published: (2023-09-01)

Bacteroides vulgatus Ameliorates Lipid Metabolic Disorders and Modulates Gut Microbial Composition in Hyperlipidemic Rats
by: Mingchao Xu, et al.
Published: (2023-02-01)

Vonoprazan a novel potassium competitive acid blocker; another leap forward
by: Maha Elsabaawy, et al.
Published: (2024-05-01)

A systematic review with meta‐analysis: Efficacy and safety of potassium‐competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis
by: Daniel M Simadibrata, et al.
Published: (2024-03-01)

Microbiota signatures associated with invasive Candida albicans infection in the gastrointestinal tract of immunodeficient mice
by: Jia-Ying Yan, et al.
Published: (2024-01-01)

Host miR-129-5p reverses effects of ginsenoside Rg1 on morphine reward possibly mediated by changes in B. vulgatus and serotonin metabolism in hippocampus
by: Chan Li, et al.
Published: (2023-12-01)

Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?
by: Soichiro Sue, et al.
Published: (2021-11-01)

Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System
by: In Mo Yoon, MD, PhD, et al.
Published: (2025-01-01)

Treatment strategies for reflux esophagitis including a potassium‐competitive acid blocker: A cost‐effectiveness analysis in Japan
by: Yasuki Habu, et al.
Published: (2021-09-01)

Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study
by: Min-Gul Kim, et al.
Published: (2023-01-01)

Adhesion of <i>Bacteroides vulgatus</i> and <i>Fusobacterium varium</i> to the Colonic Mucosa of Healthy Beagles
by: Mohsen Hanifeh, et al.
Published: (2024-07-01)

Process analysis of the anaerobe Phocaeicola vulgatus in a shake flasks and fermenter reveals pH and product inhibition
by: Laura Keitel, et al.
Published: (2024-01-01)

Effect of potassium channel blocker 4-aminopyridine pretreatment on the 6-OHDA-induced Parkinson's disease in rats
by: M. Sofiabadi, et al.
Published: (2015-06-01)

Triggering Receptor Expressed on Myeloid Cells-1 Agonist Regulates Intestinal Inflammation via Cd177+ Neutrophils
by: Dong Hyuk Seo, et al.
Published: (2021-03-01)

Carbon dioxide and trace oxygen concentrations impact growth and product formation of the gut bacterium Phocaeicola vulgatus
by: Laura Keitel, et al.
Published: (2023-12-01)

Protective role of colitis in inflammatory arthritis via propionate-producing Bacteroides in the gut
by: Hoh-Jeong Shon, et al.
Published: (2023-01-01)

Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial
by: Chang Kyo Oh, et al.
Published: (2023-12-01)

Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without <i>Helicobacter pylori</i> Infection: A Systematic Review and Network Meta-Analysis
by: Mengling Ouyang, et al.
Published: (2024-05-01)

Influence of Different Types of β-Blockers on Mortality in Patients on Hemodialysis
by: Seok-Hui Kang, et al.
Published: (2023-10-01)

Hypercontractile esophagus responsive to potassium-competitive acid blockers: a case report
by: Yuyang Shao, et al.
Published: (2022-06-01)

Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis
by: Yongqi Dong, et al.
Published: (2024-01-01)

Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy
by: Hyun Jung Lee, et al.
Published: (2024-11-01)